ISSN 1016-5169 | E-ISSN 1308-4488
Archives of the Turkish Society of Cardiology
PIONEER AF-PCI trial [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2017; 45(4): 10-14 | DOI: 10.5543/tkda.2017.04524


Murat Özdemir
Department of Cardiology, Gazi University Faculty of Medicine, Ankara, Turkey

The approach to patients with an indication for oral anticoagulation (OAC) for atrial fibrillation (AF) who undergo coronary stenting and thus need dual antiplatelet therapy has long been debated. Dual antiplatelet therapy accompanied by OAC (so called “triple therapy”) carries a high bleeding risk and thus should either be avoided or used for a limited period. The lack of relevant prospective randomised trial data have largely been overcome by the recently published PIONEER AF-PCI trial, the results of which will be summarized in this article.

Keywords: .

How to cite this article
Murat Özdemir. PIONEER AF-PCI trial. Turk Kardiyol Dern Ars. 2017; 45(4): 10-14

Corresponding Author: Murat Özdemir, Türkiye
Manuscript Language: Turkish

Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
SCImago Journal Rank: 0.348

Quick Search

Copyright © 2023 Archives of the Turkish Society of Cardiology